Work

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Year: 2022

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet

DOI: 10.1016/s0140-6736(22)01212-0

Authors: Atul Deodhar, Filip Van den Bosch, Denis Poddubnyy, Walter P Maksymowych, Désirée van der Heijde, Tae-Hwan Kim, Mitsumasa Kishimoto, Ricardo Blanco, Yuanyuan Duan, Yihan Li, Aileen L Pangan, Peter Wung, In-Ho Song

Institutions: Oregon Health & Science University, Ghent University, VIB-UGent Center for Inflammation Research, Charité – Universitätsmedizin Berlin, University of Alberta, Leiden University Medical Center, Hanyang University Seoul Hospital, Hanyang University Hospital for Rheumatic Disease, Kyorin University, Marqués de Valdecilla University Hospital, Instituto de Investigación Marqués de Valdecilla, AbbVie (United States)

Language: English

Topic: Spondyloarthritis Studies and Treatments

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4288458053

FWCI: 18.95

Cites: 31

Cited by: 154

Related to: 10